{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:22:08Z","timestamp":1791393728338,"version":"4.3.3"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mirikizumab, an anti-interleukin-23 monoclonal antibody targeting the p19 subunit, has shown efficacy in inducing and maintaining clinical remission in patients with moderately-to-severely active ulcerative colitis (UC). This report summarizes the final long-term outcomes from the LUCENT-3 open-label extension (OLE) through week (W)212 of continuous treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Among 868 participants who received mirikizumab induction therapy in the LUCENT clinical trial program, 544 achieved clinical response. Of these, 365 were rerandomized to mirikizumab maintenance, with 324 completing W52, 316 entering the OLE, and 182 completing the OLE (4\u2009years of continuous treatment), resulting in 835.3 total patient years of exposure. These analyses include efficacy and safety data from the LUCENT-3 cohort, stratified by LUCENT-1 baseline biologic experience, W52 remitter, and W52 responder status on entering the OLE study. Outcomes were analyzed using modified nonresponder imputation, traditional nonresponder imputation, and observed cases (OC) to handle missing data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At W212, W52 Maintenance Remitters showed 77.7% clinical, 77.7% corticosteroid-free (CSF), 81.3% endoscopic, 66.0% histologic-endoscopic mucosal (HEMR), 94.3% symptomatic, and 73.6% bowel urgency (BU) remission rates (OC); 67.9% achieved histologic-endoscopic mucosal improvement (HEMI), 97.1% sustained clinical response, and 92.9% achieved BU clinically meaningful improvement (CMI). At W212, W52 Maintenance Responders showed 68.7% clinical, 68.7% CSF, 70.2% endoscopic, 55.1% HEMR, 92.7% symptomatic, and 74.8% BU remission rates (OC). For W52 Maintenance Completers, reductions in stool frequency, rectal bleeding, bowel urgency, and abdominal pain from baseline were sustained to W212. W52 Maintenance Remitters and Responders achieved Inflammatory Bowel Disease Questionnaire (IBDQ; quality of life measure) response (70%) and remission (&amp;gt;66%) at W212. Across biologic failed and bionaive subgroups, efficacy results were generally similar. For over 160\u2009weeks of OLE treatment in the safety population, no new safety signals emerged from long-term exposure compared with induction and maintenance treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Mirikizumab provided sustained symptomatic, clinical, endoscopic, and histologic benefits over 4\u2009years in responding patients with moderately-to-severely active UC, including those with prior biologic failure. These treatment goals, which are integral to comprehensive disease management, support the long-term use of mirikizumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag007","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:56:47Z","timestamp":1768481807000},"page":"1023-1040","source":"Crossref","is-referenced-by-count":2,"title":["Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5762-5042","authenticated-orcid":false,"given":"Bruce E","family":"Sands","sequence":"first","affiliation":[{"name":"Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai , New York, NY 10029,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5328-8285","authenticated-orcid":false,"given":"David B","family":"Clemow","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis , IN 46285,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"D\u2019Haens","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Centers , 1081 HV, Amsterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0972-8148","authenticated-orcid":false,"given":"Peter M","family":"Irving","sequence":"additional","affiliation":[{"name":"Guy\u2019s and St Thomas' NHS Foundation Trust, London, King\u2019s College , London WC2R 2LS,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2073-4234","authenticated-orcid":false,"given":"Taku","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital , Tokyo 108-8642,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-6618","authenticated-orcid":false,"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, CHRU Nancy, INSERM NGERE, Universit\u00e9 de Lorraine , Vand\u0153uvre-l\u00e8s-Nancy, F-54500,","place":["France"]},{"name":"Division of Gastroenterology and Hepatology, McGill University Health Centre , Montreal, Quebec, H4A 3J1,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Samaan","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis , IN 46285,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Gaur","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis , IN 46285,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravneet","family":"Arora","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis , IN 46285,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"Todd","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis , IN 46285,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Moses","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis , IN 46285,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9724-054X","authenticated-orcid":false,"given":"Axel","family":"Dignass","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Agaplesion Markus Krankenhaus , 60431 Frankfurt,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"2026060322314854200_izag007-B1","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1093\/ibd\/izab016","article-title":"Ulcerative colitis narrative global survey findings: the impact of living with ulcerative colitis-patients' and physicians' view","volume":"27","author":"Dubinsky","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026060322314854200_izag007-B2","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jama.2023.15389","article-title":"Ulcerative colitis in adults: a review","volume":"330","author":"Gros","year":"2023","journal-title":"JAMA"},{"key":"2026060322314854200_izag007-B3","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet"},{"key":"2026060322314854200_izag007-B4","doi-asserted-by":"publisher","first-page":"e00578","DOI":"10.14309\/ctg.0000000000000578","article-title":"Mirikizumab regulates genes involved in ulcerative colitis disease activity and anti-TNF resistance: results from a phase 2 study","volume":"14","author":"Steere","year":"2023","journal-title":"Clin Transl Gastroenterol"},{"key":"2026060322314854200_izag007-B5","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1093\/ibd\/izae024","article-title":"Two-year efficacy and safety of mirikizumab following 104 weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension study","volume":"30","author":"Sands","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026060322314854200_izag007-B6","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1093\/ibd\/izae253","article-title":"Three-year efficacy and safety of mirikizumab following 152 weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension study","volume":"31","author":"Sands","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026060322314854200_izag007-B7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026060322314854200_izag007-B8","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.14309\/ajg.0000000000003463","article-title":"ACG clinical guideline update: ulcerative colitis in adults","volume":"120","author":"Rubin","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026060322314854200_izag007-B9","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2026060322314854200_izag007-B10","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N Engl J Med"},{"key":"2026060322314854200_izag007-B11","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"2026060322314854200_izag007-B12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.cgh.2020.09.028","article-title":"Efficacy and safety of continued treatment with mirikizumab in a phase 2 trial of patients with ulcerative colitis","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026060322314854200_izag007-B13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/pds.3891","article-title":"Guidelines for good pharmacoepidemiology practice (GPP)","volume":"25","author":"Public Policy Committee ISoP","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026060322314854200_izag007-B14","doi-asserted-by":"publisher","first-page":"i1687","DOI":"10.1093\/ecco-jcc\/jjad212.1062","article-title":"P932 corticosteroid-sparing effect of mirikizumab for the treatment of moderately-to-severely active ulcerative colitis: extended induction subgroup analysis from Phase 3 trial","volume":"18","author":"Laharie","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026060322314854200_izag007-B15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s41687-022-00522-2","article-title":"Psychometric evaluation of the Urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis","volume":"6","author":"Dubinsky","year":"2022","journal-title":"J Patient Rep Outcomes"},{"key":"2026060322314854200_izag007-B16","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/ibd.20301","article-title":"Quality of life of patients with ulcerative colitis: past, present, and future","volume":"14","author":"Irvine","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"2026060322314854200_izag007-B17","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","article-title":"Interval estimation for the difference between independent proportions: comparison of eleven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"2026060322314854200_izag007-B18","doi-asserted-by":"publisher","DOI":"10.1002\/9780470316696","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"1987"},{"key":"2026060322314854200_izag007-B19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1053\/j.gastro.2014.03.050","article-title":"Use of Hy\u2019s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury","volume":"147","author":"Robles-Diaz","year":"2014","journal-title":"Gastroenterology"},{"key":"2026060322314854200_izag007-B20","doi-asserted-by":"publisher","first-page":"otac044","DOI":"10.1093\/crocol\/otac044","article-title":"Clinical effect of mirikizumab treatment on bowel urgency in patients with moderately to severely active ulcerative colitis and the clinical relevance of bowel urgency improvement for disease remission","volume":"5","author":"Dubinsky","year":"2023","journal-title":"Crohns Colitis 360"},{"key":"2026060322314854200_izag007-B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41575-019-0211-1","article-title":"Evolving therapeutic goals in ulcerative colitis: towards disease clearance","volume":"17","author":"Danese","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026060322314854200_izag007-B22","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"2026060322314854200_izag007-B23","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1093\/ibd\/izad159","article-title":"Disease clearance as a new outcome in ulcerative colitis: a systematic review and expert consensus","volume":"30","author":"D\u2019Amico","year":"2024","journal-title":"Inflammatory Bowel Diseases"},{"key":"2026060322314854200_izag007-B24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/ecco-jcc\/jjad130","article-title":"Defining comprehensive disease control for use as a treatment target for ulcerative colitis in clinical practice: International Delphi Consensus Recommendations","volume":"18","author":"Schreiber","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026060322314854200_izag007-B25","doi-asserted-by":"publisher","first-page":"101990","DOI":"10.1016\/j.bpg.2025.101990","article-title":"Treatment targets in IBD: is it time for new strategies?","volume":"77","author":"Fanizzi","year":"2025","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2026060322314854200_izag007-B26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/ph18010078","article-title":"Advancing therapeutic targets in IBD: emerging goals and precision medicine approaches","volume":"18","author":"Centanni","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026060322314854200_izag007-B27","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1136\/gutjnl-2023-329964","article-title":"Different levels of healing in inflammatory bowel diseases: mucosal, histological, transmural, barrier and complete healing","volume":"72","author":"Neurath","year":"2023","journal-title":"Gut"},{"key":"2026060322314854200_izag007-B28","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/ecco-jcc\/jjw177","article-title":"Long-term efficacy of vedolizumab for ulcerative colitis","volume":"11","author":"Loftus","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2026060322314854200_izag007-B29","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1111\/apt.16119","article-title":"Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy","volume":"52","author":"Panaccione","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2026060322314854200_izag007-B30","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1093\/ecco-jcc\/jjad050","article-title":"Resolving histological inflammation in ulcerative colitis with mirikizumab in the LUCENT induction and maintenance trial programmes","volume":"17","author":"Magro","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026060322314854200_izag007-B31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40271-019-00407-5","article-title":"A qualitative research for defining meaningful attributes for the treatment of inflammatory bowel disease from the patient perspective","volume":"13","author":"Louis","year":"2020","journal-title":"Patient"},{"key":"2026060322314854200_izag007-B32","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1007\/s11136-020-02606-2","article-title":"An assessment of symptom burden in \u00adinflammatory bowel diseases to develop a patient preference-weighted symptom score","volume":"29","author":"van Deen","year":"2020","journal-title":"Qual Life Res"},{"key":"2026060322314854200_izag007-B33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s41687-022-00439-w","article-title":"Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults","volume":"6","author":"Dubinsky","year":"2022","journal-title":"J Patient Rep Outcomes"},{"key":"2026060322314854200_izag007-B34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2147\/PROM.S378759","article-title":"Exploring disease remission and bowel urgency severity among adults with moderate to severe ulcerative colitis: a qualitative study","volume":"13","author":"Dubinsky","year":"2022","journal-title":"Patient Relat Outcome Meas"},{"key":"2026060322314854200_izag007-B35","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"2026060322314854200_izag007-B36","doi-asserted-by":"publisher","first-page":"5318","DOI":"10.3390\/jcm10225318","article-title":"Primary failure to an anti-TNF agent in inflammatory bowel disease: switch (to a second anti-TNF agent) or swap (for another mechanism of action)?","volume":"10","author":"Gisbert","year":"2021","journal-title":"J Clin Med"},{"key":"2026060322314854200_izag007-B37","doi-asserted-by":"publisher","first-page":"S047","DOI":"10.1093\/ecco-jcc\/jjab073.048","article-title":"DOP09 mirikizumab-induced transcriptome changes in patient biopsies at week 12 are maintained through week 52 in patients with ulcerative colitis","volume":"15","author":"Johnson","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026060322314854200_izag007-B38","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1093\/ecco-jcc\/jjaa023","article-title":"Quality of care standards in inflammatory bowel diseases: a European Crohn\u2019s and Colitis Organisation [ECCO] position paper","volume":"14","author":"Fiorino","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026060322314854200_izag007-B39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","article-title":"Ulcerative colitis","volume":"6","author":"Kobayashi","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2026060322314854200_izag007-B40","volume-title":"Ulcerative Colitis: Developing Drugs for Treatment Guidance for Industry","author":"US Food and Drug Administration","year":"2022"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/6\/1023\/67224105\/izag007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/6\/1023\/67224105\/izag007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:31:58Z","timestamp":1780540318000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/6\/1023\/8505596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3,2]]},"published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag007","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,3,2]]}}}